Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in heart failure patients with reduced ejection fraction
2017-001341-27Phase 2Completed
- Sponsor
- Morten Schou
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of empagliflozin in heart failure with reduced ejection fraction (HFrEF), sponsored by Morten Schou. Started Apr 2017; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2017-001341-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001341-27.